SHIMIN HU

TitleAssistant Professor
InstitutionMD Anderson
DepartmentHematopathology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Tang G, Goswami RS, Liang CS, Bueso-Ramos CE, Hu S, DiNardo C, Medeiros LJ. Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. Am J Clin Pathol. 2015 Jul; 144(1):78-86. PMID: 26071464.
      Citations: 4     Fields:    Translation:HumansCells
    2. Chen Z, Wang W, Verstovsek S, Cortes JE, Medeiros LJ, Hu S. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Int J Lab Hematol. 2015 Dec; 37(6):e150-2. PMID: 26086872.
      Citations: 1     Fields:    Translation:Humans
    3. Wang XI, Yin CC, Qazilbash MH, Hu S, Lu G. Clinical significance of acquired cytogenetic clones in patients with treated follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2015 May; 15(5):262-9. PMID: 25573378.
      Citations:    Fields:    Translation:Humans
    4. Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver N. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e115-8. PMID: 24589157.
      Citations: 5     Fields:    Translation:Humans
    5. Hu S, Bueso-Ramos CE, Verstovsek S, Miranda RN, Yin CC, McDonnell T, Medeiros LJ, Lin P. Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):629-33. PMID: 23800601.
      Citations: 3     Fields:    Translation:Humans
    6. Manola A, Kourelis TV, Busman B, Hu S, Marks P, Thompson PD. Mastocytosis causing refractory hypotension after coronary angiography. Int J Cardiol. 2012 Apr 19; 156(2):e43-4. PMID: 21917341.
      Citations:    Fields:    Translation:Humans
    7. Mei Y, Hahn AA, Hu S, Yang X. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2. J Biol Chem. 2011 Oct 14; 286(41):35380-35387. PMID: 21849505.
      Citations: 40     Fields:    Translation:HumansCells
    8. Hu S, Mrak RE, Goldblatt PJ. Tripartite components of a hepatocellular carcinoma with distinct immunohistochemical and metastatic features. Conn Med. 2010 Feb; 74(2):79-83. PMID: 20218042.
      Citations:    Fields:    Translation:HumansCells
    9. Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X, Chen YH. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008 May 02; 133(3):415-26. PMID: 18455983.
      Citations: 155     Fields:    Translation:HumansAnimalsCells
    10. Park SM, Hu S, Lee TH, Yang X. Ubiquitination mediated by inhibitor of apoptosis proteins. Methods Enzymol. 2008; 446:225-35. PMID: 18603125.
      Citations:    Fields:    Translation:HumansCells
    11. Hu S, Alcivar A, Qu L, Tang J, Yang X. CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation. Cell Cycle. 2006 Jul; 5(13):1438-42. PMID: 16775419.
      Citations: 8     Fields:    Translation:HumansCells
    12. Hu S, Du MQ, Park SM, Alcivar A, Qu L, Gupta S, Tang J, Baens M, Ye H, Lee TH, Marynen P, Riley JL, Yang X. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest. 2006 Jan; 116(1):174-81. PMID: 16395405.
      Citations: 45     Fields:    Translation:HumansCells
    13. Alcivar A, Hu S, Tang J, Yang X. DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene. 2003 Jan 16; 22(2):291-7. PMID: 12527898.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    14. Hu S, Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem. 2003 Mar 21; 278(12):10055-60. PMID: 12525502.
      Citations: 80     Fields:    Translation:HumansCells
    15. Hu S, Yang X. dFADD, a novel death domain-containing adapter protein for the Drosophila caspase DREDD. J Biol Chem. 2000 Oct 06; 275(40):30761-4. PMID: 10934188.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    16. Hu S, Tamada K, Ni J, Vincenz C, Chen L. Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics. 1999 Nov 15; 62(1):103-7. PMID: 10585776.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    17. Guo RF, Ward PA, Hu SM, McDuffie JE, Huber-Lang M, Shi MM. Molecular cloning and characterization of a novel human CC chemokine, SCYA26. Genomics. 1999 Jun 15; 58(3):313-7. PMID: 10373330.
      Citations: 2     Fields:    Translation:HumansCells
    18. Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM. Caspase-14 is a novel developmentally regulated protease. J Biol Chem. 1998 Nov 06; 273(45):29648-53. PMID: 9792675.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    19. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem. 1997 Jul 11; 272(28):17255-7. PMID: 9211860.
      Citations: 73     Fields:    Translation:HumansCells
    20. Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem. 1997 Apr 11; 272(15):9621-4. PMID: 9092488.
      Citations: 78     Fields:    Translation:AnimalsCells
    21. Clinical significance of acquired loss of the X chromosome in bone marrow. Leukemia Research. 47:109-113.
    22. ALK-positive large b-cell lymphoma. American Journal of Surgical Pathology. 41:25-38.
    23. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer Journal. 6.
    24. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer Journal. 6.
    25. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    26. De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated with Poor Prognosis. Pediatric Hematology and Oncology. 32:535-547.
    27. Hepatitis B virus-associated diffuse large B-cell lymphoma. Oncotarget. 6:25061-25075.
    28. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Annals of Hematology. 1-4.
    29. The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. Modern Pathology.
    30. Mantle Cell Lymphoma With MYC Rearrangement. American Journal of Surgical Pathology.
    31. Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Modern Pathology.
    32. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia.
    33. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    34. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 126:1699-1706.
    35. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127:2742-2750.
    36. Double-hit follicular lymphoma with MYC and BCL2 translocations. Human Pathology. 58:72-77.
    37. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients. Journal of Hematology and Oncology. 8.
    38. Tetraploidy/near-tetraploidy acute myeloid leukemia. Leukemia Research. 53:20-27.
    39. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology.
    40. BCR-ABL1-negative acute myeloid leukaemia relapsing as BCR-ABL1-positive disease. British Journal of Haematology.
    41. T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. International Journal of Laboratory Hematology.
    42. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia. Journal of Hematology and Oncology. 8.
    HU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (178)
    Explore
    _
    Co-Authors (13)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _